GlassScriptPhysician profile
Jason C Dy
NPI 1396710265
$8,719.55
in general payments reported to CMS, 2019-2025
53 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.62 · 2020: $60.26 · 2021: $771 · 2022: $1,051 · 2023: $2,257 · 2024: $2,429 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,817.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,816.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,550.22 | 2021-2025 | Vraylar, Ubrelvy, Linzess |
| Lilly USA, LLC | $896.91 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $812.75 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $623.50 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $580.58 | 2022-2025 | Airsupra, Farxiga, Breztri |
| Janssen Pharmaceuticals, INC | $561.79 | 2021-2025 | Spravato, Xarelto |
| Phathom Pharmaceuticals, INC. | $370.31 | 2024-2025 | Voquezna |
| Glaxosmithkline, LLC. | $316.96 | 2021-2025 | Shingrix, Arexvy, Bexsero |
| Merck Sharp & Dohme LLC | $259.50 | 2021-2025 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Amgen INC. | $227.91 | 2022-2025 | Evenity, Prolia |
| Currax Pharmaceuticals LLC | $223.11 | 2021-2024 | Onzetra Xsail, Contrave, Nexletol |
| Exact Sciences Corporation | $155.22 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Xeris Pharmaceuticals, INC. | $152.00 | 2022-2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.43 | 2021-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $131.26 | 2022 |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Dy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.